



GO NORTE INTERNATIONAL GU DEBATES

8th-9th

OCTOBER
2026



X #GonorteGUDebates

VENUE

PARADOR DE LIMPIAS

Fuente del Amor s/n,
39820, Limpías (Cantabria)

ORGANIZED BY



GONORTE
Grupo Oncológico

08:30 REGISTRATION

09:00-09:10 OPENING

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Dra. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona

**09:10-11:50 SESSION 1. NON-MUSCLE INVASIVE BLADDER CANCER:
ARE NEW TREATMENTS READY FOR PRIME TIME?**

Chairs:

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. José Rubio, Urology Department, Hospital Vithas Valencia 9 de Octubre

09:15-09:30 Clinical Vignette

Dr. Javier Pizzarello, Urology Department, Hospital Vithas Valencia 9 de Octubre

09:30-09:45 NMIBC: What do I need to know to understand drug development in this setting?

Dr. Jozefina Casuscelli, Urology Department, LMU University Hospital, Munich, Germany

09:45-10:00 New I.O. based treatments are ready for prime time in BCG naïve NMIBC patients

Dr. Javier Puente, Genitourinary Medical Oncology Department, Hospital Universitario San Carlos, Madrid

10:00-10:15 New IO. based treatments are not ready for prime time in BCG naïve NMIBC patients

Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid

10:15-10:30 Radiotherapy-based treatments as an emerging strategy in HR NMIBC

Dr. Xavier Maldonado, Radiology Department, Vall d'Hebron Barcelona Hospital

THURSDAY, OCTOBER 8th

10:30-10:45 **Intravesical drug-delivery systems in BCG-naïve disease: Evidence and limitations**

Dr. Bernardo Herrera, Urology Department, Hospital Universitario Virgen de la Victoria, Málaga

10:45-11:15 **Discussion**

11:15-11:50 **COFFEE BREAK** ☕

11:50-13:20 SESSION 2. MUSCLE INVASIVE BLADDER CANCER: APPROACHING A CLASSIC DISEASE IN A NEW ERA

Chairs:

Dra. Elena Sevillano, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

Dr. Jerónimo Barrera, Urological Radiology Department, Hospital Clínico San Carlos, Madrid

11:50-12:05 **Clinical Vignette**

Dra. Joseline M. San Miguel, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

12:05-12:20 **Do I have to convince my radiologist to perform MRI in MIBC? From its role in initial staging to potential biomarker of response**

Dr. Richard Mast, Radiology Department, Vall d'Hebron Barcelona Hospital

12:20-12:35 **Variant histologies in MIBC: Which ones, how often and how much should condition my perioperative treatment selection?**

Dra. Ainara Azueta, Pathology Department, Hospital Universitario Basurto, Bilbao

12:35-12:50 **Do blood or urine biomarkers have any role in guiding perioperative treatment?**

Dr. Yohan Lorient, Medical Oncology Department, Institut Gustave Roussy, Villejuif, France

12:50-13:20 **Discussion**



THURSDAY, OCTOBER 8th

**13:20-14:05 MEET THE EXPERT SYMPOSIUM | IMFINZI,
DRIVING THE CHANGE IN MIBC**

Chair: **Dr. Ignacio Durán**, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Speakers:

Dr. Javier Puente, Genitourinary Medical Oncology Department, Hospital Universitario San Carlos, Madrid

Dr. Carlos Álvarez, Hospital Universitario Central de Asturias, Oviedo

Sponsored by: **AstraZeneca** 

14:05-15:30 LUNCH BREAK

**15:30-17:00 SESSION 3. DEBATING BEST TREATMENT APPROACH
IN MUSCLE INVASIVE BLADDER CANCER**

Chairs:

Dr. Enrique Grande, Medical Oncology Department, Quirónsalud, Madrid

Dr. Mario Álvarez Maestro, Urology Department, Hospital Universitario La Paz, Madrid

15:30-15:50 **Are perioperative ADC combinations the new default strategy?**
Dr. Patrizia Giannatempo, Medical Oncology Department, Istituto Nazionale dei Tumori, Milan, Italy

15:50-16:10 **Perioperative chemotherapy plus checkpoint inhibition:
Which and to whom in 2026?**
Dr. Syed A. Hussain, Medical Oncology Department, University of Sheffield, Sheffield Teaching Hospitals NHS Trust, UK

16:10-16:30 **What if I want to preserve my bladder? Current and future
bladder sparing strategies in MBIC**
Dr. Terence Friedlander, Genitourinary Medical Oncology, University of California, San Francisco, USA

16:30-17:00 ***Discussion***

THURSDAY, OCTOBER 8th

17:00-17:45 MEET THE EXPERT SYMPOSIUM | TRANSFORMING THE BLADDER CANCER CONTINUUM: FROM PERIOPERATIVE MIBC TO ADVANCED DISEASE

Sponsored by:  **astellas**

17:00-17:05 Welcome and Introduction

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

17:05-17:20 Keynote Lecture

EV+P Across Stages and Patient Population

Dr. Terence Friedlander, Genitourinary Medical Oncology, University of California San Francisco, USA

17:20-17:30 Interactive Expert Panel

17:30-17:45 Putting the Patient at the Center: "Translating Evidence into Practice"

Dr. Alfonso Gómez de Liaño, Medical Oncology Department, Complejo Hospitalario Universitario Insular de Gran Canaria

Dr. Isabel Galante, Genitourinary Medical Oncology Department, Hospital Clínico San Carlos, Madrid

Case 1: Full-Dose Therapy to Achieve Deep Response in La/m UC

Case 2: MIBC cis-ineligible pts with impaired renal function

17:45-18:20 COFFEE BREAK ☕

18:20-19:05 MEET THE EXPERT SYMPOSIUM | ADVANCED DISEASE

Chair:

Dra. María José Juan Fita, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

Speakers:

Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers Program, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center

Sponsored by:  **MSD**



THURSDAY, OCTOBER 8th

19:05-19:15 2024 GO NORTE GRANTS

19:05-19:10 **Mechanisms of resistance to immunotherapy in patients with non-urothelial histological variant metastatic urinary tract tumours (CHESSY PROJECT)**

Dr. Diego Cacho, Medical Oncology Department, Hospital Universitario. Marqués de Valdecilla – IDIVAL, Santander

19:10-19:15 **Prognostic and predictive value of low-density neutrophils in first-line treatment of metastatic renal cell carcinoma with immune checkpoint inhibitors**

Dr. Ibon Gurrutxaga, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona

19:15 -19:45 KEYNOTE LECTURE

Treating Bladder Cancer in 2030: What does the future hold?

Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers Program, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center

19:45-19:50 CLOSING OF THE DAY

20:00 **GET TOGETHER COCKTAIL AND DINNER** 🍷

08:00-08:15 OPENING

Dr. Ricardo Fernández, Medical Oncology Department, Hospital Universitario de Cruces, Bilbao

Dr. Carmen Santander, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza

08:15-09:35 SESSION 4. PROSTATE CANCER

Chairs:

Dr. Miguel Ángel Climent, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

Dra. Estefania Linares, Urology Department, Hospital Universitario La Paz, Madrid

08:15-08:30 The perioperative treatment of high-risk Prostate Cancer in 2026: Where do things stand after PROTEUS?

Dr. David Lorente, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

08:30-08:45 Advanced hormone sensitive disease: Is the triplet vs doublet debate over?

Juan Francisco Rodríguez-Moreno, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

08:45-09:00 Optimizing androgen receptor-targeted therapy in mCRPC in 2026: Present options and near future

Urbano Anido, Medical Oncology Department, Complejo Hospitalario Universitario de Santiago de Compostela

09:00-09:15 Positioning PARP Inhibitors in mCRPC: The 2026 Landscape

Dr. Enrique González-Billalabeitia, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

09:15 - 09:35 Discussion



FRIDAY, OCTOBER 9th

09:35-10:20 MEET THE EXPERT SYMPOSIUM | mHSPC: THE ADVENT OF PRECISION MEDICINE IN RESPONSE TO AN UNMET MEDICAL NEED

Chair:

Dr. Javier Puente, Genitourinary Medical Oncology Department, Hospital Universitario San Carlos, Madrid

Speakers:

Dr. David Olmos, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. David Lorente, Medical Oncology Department, Instituto Valenciano de Oncología – IVO, Valencia

Sponsored by: **Johnson&Johnson**

10:20-10:55 COFFEE BREAK ☕

11:00-11:47 MEET THE EXPERT SYMPOSIUM | PLUVICTO IN mCRPC: REDEFINING THE THERAPEUTIC ALGORITHM

Chairs:

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Iratxe Fernández Tercero, Nuclear Medicine Department, Hospital Universitario de Cruces, Bilbao

Sponsored by: **NOVARTIS**

11:00-11:03 Welcome and introduction

11:03-11:12 Positioning of Pluvicto in the therapeutic landscape of mCRPC in Spain in 2026

Dr. Naiara Sagaztibeltza, Medical Oncology Department, Hospital Universitario de Donostia, San Sebastian

11:12-11:21 Imaging-based selection criteria: the Nuclear Medicine perspective

Dr. Zulema Nogareda, Nuclear Medicine Department, Complejo Hospitalario Universitario de Santiago de Compostela

11:21 - 11:35 **Pluvicto: lessons from clinical experience**

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

11:35-11:45 **Discussion**

11:45-11:47 **Closing Remarks**

11:50-13:05 **SESSION 5. HIGH RISK LOCALIZED RENAL CANCER**

Chairs:

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

Dr. Mario Domínguez, Urology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

11:50-12:00 **Clinical Vignette**

Dr. Ángel Fernández, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

12:00-12:15 **Estimating risk after nephrectomy: Are we all in the same page? Are we overtreating?**

Dr. Teresa Alonso, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid

12:15-12:30 **Reshaping adjuvant treatment in 2026: Is angiogenesis back?**

Dr. Dan Heng, Head, Medical Oncology, Arthur JE Child Comprehensive Cancer Centre, Calgary, Canada

12:30-12:45 **I am in favor of systemic treatment first? Role of neoadjuvant treatment in high risk RCC**

Dr. Axel Bex, Genitourinary Medical Oncologist Department, Amsterdam University Medical Center, The Netherlands Cancer Institute

12:45-13:05 **Discussion**



FRIDAY, OCTOBER 9th

13.05-14:10 **SESSION 6. ADVANCED RENAL CANCER AND OTHER VHL MEDIATED DISEASES**

Chairs:

Dr. Jesús García Donas, Medical Oncology Department, Hospital Universitario HM Sanchinarro - Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

Dr. Xavier García Del Muro, Genitourinary and Sarcoma Unit. Institut Català d'Oncologia, L'Hospitalet de Llobregat

13:05-13:20 **First line mRCC: IO-IO vs IO-TKI: Is the eternal debate over?**

Dr Lisa Pickering, Medical Oncology Department, The Royal Marsden NHS Foundation Trust, London, UK

13:20-13:35 **Sequencing treatments in the advanced setting: Is it clear in 2026?**

Dr. Cristina Suárez, Medical Oncology Department, Vall d'Hebron Barcelona Hospital

13:35-13:50 **Inhibiting HIF in VHL syndrome: A life changer for patients?**

Dr. Guillermo De Velasco, Medical Oncology Department, Hospital 12 de Octubre, Madrid

13:50-14:10 **Discussion**

14:10-14:40 **CLOSING LECTURE**

Curing the Incurable? Rethinking long-term disease control in advanced RCC

Dr. Dan Heng, Head, Medical Oncology, Arthur JE Child Comprehensive Cancer Centre, Calgary, Canada

14:40 **CLOSING OF THE SYMPOSIUM**

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Dr. Ricardo Fernández, Medical Oncology Department, Hospital Universitario de Cruces, Bilbao

SPONSORS

PLATINUM



astellas

AstraZeneca



NOVARTIS



MSD

SILVER



IPSEN

MERCK

BRONZE



Bristol Myers Squibb™

EXELIXIS®

Pfizer



RECORDATI
RARE DISEASES



AUSPICES

aseica



GUARD CONSORTIUM
GU-Alliance for Research and Development

Solicitada la acreditación a la Comisión de Formación Continuada del Sistema Nacional de Salud y de la Consejería de Sanidad de la Comunidad de Cantabria.

La asistencia al curso completo es obligatoria para obtener la acreditación. No recibirán los créditos del sistema acreditador ni estudiantes, ni médicos internos residentes, ya que están excluidos del mismo.

Secretaría técnica

tactics

📍 Barcelona · Madrid

📞 93 451 17 24

✉️ info@tacticsmd.net

🌐 www.tacticsmd.net